

This article was originally published [here](#)

Niraparib delivered the desired result when given as monotherapy in the patient population, irrespective of biomarker status. The results of the PRIMA trial were presented at the 2019

The post [GSK's niraparib meets PFS goal in phase 3 PRIMA trial](#) appeared first on [Pharmaceutical Business review](#).